Measles Vaccine in HCW

Covid19 Clinical Trial

— MV-COVID19  

Official title:

Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT04357028
• Other study ID #: N-30-2020
• Status: Suspended
• Phase: Phase 3
• Start date: July 13, 2020
• Est. completion date: January 1, 2021

Study information

• Verified date: December 2020
• Source: Kasr El Aini Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is that cross-protective antibodies against measles vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV,

The primary objective of the present study is to determine the benefit of measles vaccine in health care professional to decrease the incidence of COVID-19.

We Hypothesized that, measles vaccine may lower the incidence of serologically proven SARS-CoV-2 infection and reported respiratory illness

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 200
• Est. completion date: January 1, 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Age 18-50 years old

• Subjects who are willing to comply with the requirements of the study protocol and scheduled visits (for example, completion of the subject diary, return for follow-up visits) and who are willing to make themselves available for the duration of the study with access to a consistent means of telephone contact

Exclusion Criteria:

• acute severe illness

• recent receipt of a blood product

• history of thrombocytopenia

• Pregnant females

• any chronic medical condition

• Any participant receiving any immune suppressive medication

• Immunocompromised staff

• Participants who have egg allergy

• Participants who care for immune compromised hosts

• Participants who test positive for COVID-19 serology prior to randomization

Related Conditions & MeSH terms

• Covid19
• Measles

Intervention

Drug:
• Measles-Mumps-Rubella Vaccine
Measles mumps Rubella vaccine is a weak attenuated life vaccine
• Placebos
0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm

Locations

Country	Name	City	State
Egypt	Cairo University Hospital	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Kasr El Aini Hospital

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	COVID-19 disease incidence	Number of participants with asymptomatic or mild COVID-19 disease defined as fever (using self-reported questionnaire), plus at least one sign or symptom of respiratory disease including cough, runny/blocked nose (using self-reported questionnaire), plus positive SARS-Cov-2 test (PCR or serology)	Time Frame: Measured over the 6 months following randomization
Secondary	SARS-CoV-2 pneumonia	Number of pneumonia cases (abnormal chest X-ray) (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test	Time Frame: Measured over the 6 months following randomization
Secondary	Critical care admission duration with SARS-CoV-2	Number of days admitted to critical care (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test	Time Frame: Measured over the 6 months following randomization
Secondary	Oxygen therapy with SARS-CoV-2	Need for oxygen therapy (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test	Time Frame: Measured over the 6 months following randomization